ArticleFrontiers in pediatrics2020
Resolution of Giant Coronary Aneurisms in a Child With Refractory Kawasaki Disease Treated With Anakinra.
Article in Frontiers in pediatrics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06697431 (A Randomized, Controlled, Open-label, Non Inferiority KawasakI Trial With Anakinra), which is not on this map. Cited by 10 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Controlled, Open-label, Non Inferiority KawasakI Trial With Anakinra
Who cites it
10 citing papers in PubMed, 3 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Anakinra for intravenous immunoglobulin-resistant Kawasaki disease: a systematic literature review.RMD open · 2026Pooled it
- Anakinra use in pediatric kawasaki disease: inflammation control, coronary artery outcomes, and safety.Pediatric rheumatology online journal · 2026Pooled it
- Efficacy and safety of infliximab in the treatment of Kawasaki disease: A systematic review and meta-analysis.European journal of pediatrics · 2024Pooled it
- Multiresistant Kawasaki Disease in a Young Infant with Giant Aneurysms Growing Fast.Journal of cardiovascular development and disease · 2024Article
- Review
- Anakinra in Paediatric Rheumatology and Periodic Fever Clinics: Is the Higher Dose Safe?Frontiers in pediatrics · 2022Article
- Case Report: Kawasaki Shock Syndrome With Polycyclic Eruption: A Peculiar Brain Imaging.Frontiers in pediatrics · 2021Article
- Early anti IL-1 treatment replaces steroids in refractory Kawasaki disease: clinical experience from two case reports.Therapeutic advances in musculoskeletal disease · 2021Article
- Anakinra for Treatment-Resistant Kawasaki Disease: Evidence from a Literature Review.Paediatric drugs · 2020Review
- Disease and age-related inequalities in paediatric research, funding and communication: Lessons from the COVID-19 pandemic.Acta paediatrica (Oslo, Norway : 1992) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kawasaki disease (KD) is an acute, febrile illness of unknown etiology that mainly affects children under 5 years of age. intravenous immunoglobulin (IVIG), the standard treatment, has reduced coronary involvement to <5%. Patients who do not improve after an initial IVIG have a higher risk of developing coronary arteries aneurysms, and its optimal treatment remains controversial. We present a case of IVIG, steroids, and infliximab-resistant KD in a 9-month-old child, which developed giant aneurysms and was successfully treated with anakinra, a recombinant antagonist of the IL-1 receptor. In our case, the introduction of IL-1 receptor antagonist therapy seems to have blocked the disease from both a clinical and a laboratory point of view. We also noted a very rapid regression of coronary aneurysms passed from giant aneurysms to small ones, or, as in the case of the anterior descending artery, the complete disappearance of the aneurysm formation. We think that our case adds more evidences to the potential role of IL-1RA as therapy in some selected cases of refractory KD, in particular with severe involvement of coronary arteries, although new efficacy trials are needed to better understand the role of Anakinra in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.